Sign in
Taking peoplePhase 2

Oral NXC-736 tested for alopecia areata in adults

Tests the pill NXC-736 against placebo in adults with alopecia areata.

Key facts

Who runs it
NEXTGEN Bioscience
Where
South Korea2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
Status
Recruiting
Phase
Phase 2
People taking part
73 people, planned
Started
1 Sept 2024
Expected to end
31 Jan 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • NXC736
  • Placebo
Record updated
13 April 2026

Who can take part

The trial is looking for adults with moderate or severe alopecia areata, a condition where the immune system causes patchy hair loss. It tests NXC736 taken by mouth against a placebo.

Age
19 to 65 years
Sex
Men and women
Disease stage
Moderate or severe alopecia areata, with a SALT hair-loss score of 25% ≤ SALT < 95%. The current episode of hair loss has lasted ≥6 months but <8 years. There has been no clear hair regrowth in the last 6 months.
Earlier treatment
People who have used a Janus kinase (JAK) inhibitor before, by mouth or on the skin, cannot join. This includes taking part in JAK inhibitor studies.
Main reasons for not taking part
  • Other types of hair loss, such as scarring alopecia, traction alopecia, androgenic alopecia or telogen effluvium
  • Active scalp inflammation, scalp infection or scalp psoriasis
  • Any other scalp condition that could disturb the hair-loss score
  • Past use of a JAK inhibitor
  • Not willing to keep the same hair style and color during the study
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Men or women between ≥19 and ≤65 years of age at the time of informed consent
  • Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT < 95% at Screening and Day 1/Baseline
  • Current episode of hair loss for ≥6 months but <8 years
  • Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator
  • Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study

Who cannot take part

  • Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors
  • Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment
  • Participants with the following medical history confirmed during screening:; ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring alopecia [including central centrifugal cicatricial alopecia], traction alopecia, androgenic alopecia, telogen effluvium, etc.)

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Alopecia areata

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

The 2 groups in the trial

  • NXC736Treatment being tested
  • PlaceboPlacebo, for comparison

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata
Plain-language title
Oral NXC-736 tested for alopecia areata in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06104839, who can take part
Record updated
13 April 2026